Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ILK | Q13418 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 8/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757553 | 0.90 | APP (0.41) | ILKAPPMGAMGAASI | |
| SCHEMBL5757037 | 0.88 | CASP3 (0.46) | ILKAPPMGAMGAASI | |
| SCHEMBL5754098 | 0.80 | ILK (0.56) | ILKAPPF10 | |
| SCHEMBL5756441 | 0.79 | MAPT (0.61) | ILKAPPMGAMGAASI | |
| SCHEMBL27604009 | 0.78 | APP (0.41) | ILKAPPMGAMGAASI | |
| SCHEMBL5756448 | 0.78 | ILK (0.52) | ILKKDM4ENPC1RAB9A | |
| SCHEMBL5758629 | 0.77 | ILK (0.51) | ILKKDM4ENPC1RAB9A | |
| SCHEMBL5757292 | 0.77 | KMT2A (0.48) | GAAMAPTNPC1RAB9ANPSR1 | |
| SCHEMBL5758116 | 0.75 | RAB9A (0.50) | ILKAPPMGAMGAASI | |
| SCHEMBL7187329 | 0.74 | MAPT (0.72) | ILKAPPMGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539723-B1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-24 | — | — | EP | claimed |
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ASTRAZENECA (SE) | 2006-05-18 | — | — | US | claimed |
| CN-1675189-A | New use of benzothiazole derivatives | ASTRAZENECA AB (SE) | 2005-09-28 | — | — | CN | claimed |
| EP-1539723-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | claimed |
| WO-2004016600-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | claimed |
| EP-1539723-B1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ASTRAZENECA (SE) | 2006-05-18 | — | — | US | disclosed |
| CN-1675189-A | New use of benzothiazole derivatives | ASTRAZENECA AB (SE) | 2005-09-28 | — | — | CN | disclosed |
| EP-1539723-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016600-A1 | NOVEL USE OF BENZOTHIAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106015-A1 | Novel use of benzothiazole derivatives | ITK, WEE2, WEE1 | ILK 1798/4885APP 3980/4885MGAM 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.